US IPO Pipeline SEC S-1 Filings — April 06, 2026

06-04-2026

20/20 Biolabs, Inc. filed an S-1 registration statement on April 6, 2026, to register shares related to its agreements with Streeterville, including up to $40,000,000 in Series E convertible preferred stock via a Preferred Purchase Agreement and a convertible note with $295,000 principal outstanding as of December 31, 2025. The company also raised $712,256 through equity crowdfunding convertible notes and $70,000 via private convertible notes, both featuring 80% conversion discounts that pose significant dilution risk upon IPO or qualified financings. Warrants issued include 3,502,627 shares exercisable at $11.42 and others to placement agent Maxim for 2,169 shares at $8.16.

• ·Equity crowdfunding notes converted into common stock on February 25, 2026.
• ·Initial Registration Statement declared effective by SEC on February 17, 2026.
• ·Preferred Purchase Agreement first closing on November 17, 2025; second closing February 19, 2026.
• ·Streeterville has most favored nation rights for more favorable terms in future securities.
• ·Company formerly known as 20/20 GeneSystems, Inc. (name change September 22, 2015).

06-04-2026

Mountain Crest Acquisition 6 Corp., a blank check company (SPAC), filed an S-1 registration statement on April 6, 2026, for an IPO with units to list on Nasdaq under symbols MCAH and MCAHR upon separate trading. The filing extensively discloses risks of pursuing a business combination with PRC-based targets, including VIE structure uncertainties, CSRC filing requirements, cybersecurity reviews, and potential government interventions that could render securities worthless. No specific business combination target or financial performance data is provided, emphasizing pre-operational status with no subsidiaries, dividends, or cash transfers to date.

• ·CSRC Trial Measures promulgated February 17, 2023, effective March 31, 2023.
• ·New Measures for Cybersecurity Review effective February 15, 2022.
• ·CSRC filing exemptions for prior listings completed before September 30, 2023.
• ·Risk factors detailed starting on page 81, including VIE enforceability and currency controls on page 98.
• ·No permissions required from PRC authorities like CSRC or Cyberspace Administration of China for this offering as of prospectus date.

06-04-2026

Legence Corp. filed an S-1 registration statement on April 6, 2026, presenting unaudited pro forma condensed combined financial information reflecting its acquisition of The Bowers Group, Inc. (Bowers) completed on January 2, 2026, for total estimated consideration of $426.6 million, including $283.1 million cash, 2,551,672 shares of Class A common stock valued at $98.6 million, and $44.9 million deferred consideration. Pro forma combined revenue for the year ended December 31, 2025, reaches $3,449,898 thousand, combining Legence's historical $2,550,491 thousand with Bowers' $902,357 thousand after adjustments, while pro forma total assets stand at $3,265,176 thousand as of December 31, 2025. The acquisition was financed via a $200.0 million incremental term loan, cash on hand, and revolver borrowings, following Legence's prior IPO in September 2025 which raised net proceeds of $780.2 million.

• ·Pro forma combined total liabilities as of December 31, 2025: $2,390,907 thousand.
• ·Pro forma combined total equity as of December 31, 2025: $874,269 thousand.
• ·IPO commenced trading on Nasdaq Global Select Market on September 12, 2025, and closed on September 15, 2025.
• ·Acquisition shares subject to lock-up through March 10, 2026.

06-04-2026

TEN Holdings, Inc. (XHLD), a holding company for TEN Events, Inc., filed an S-1 registration statement on April 6, 2026, for a public offering of common stock, with shares already listed on Nasdaq at a closing price of $1.51 on April 2, 2026. Revenue from core virtual and hybrid events declined 15.6% YoY to $2.7 million in 2025 from $3.2 million in 2024 (88.2% of total revenue), while physical events revenue grew 33.3% to $0.4 million (11.8% of total). The company supported 248 virtual/hybrid events with 525,812 attendees in 2025 and held $1.6 million in cash as of December 31, 2025.

• ·Common stock closing price $1.51 on April 2, 2026.
• ·Stock options outstanding as of Dec 31, 2025: 197,609 shares at weighted average exercise price of $6.82 per share.
• ·90-day lock-up agreements for directors, officers, and principal stockholders.
• ·Over-Allotment Option for underwriter to purchase up to additional shares within 45 days.

06-04-2026

LB Pharmaceuticals Inc. (LBRX) filed an S-1 registration statement on April 6, 2026, to permit Selling Stockholders to resell shares, with the company receiving no proceeds from such resales except nominal amounts from Pre-Funded Warrants. The company has never paid dividends and intends to retain earnings for operations and growth. The filing discloses the management team and board as of December 31, 2025, highlighting experienced executives from biopharma firms like Carmot Therapeutics and Atara Biotherapeutics.

• ·Company bears costs of registration but not Selling Stockholder's sales-related expenses.
• ·No present intention to pay cash dividends for the foreseeable future.
• ·Management and board information as of December 31, 2025.